Stay updated with breaking news from Annie Starr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shareholders elect industry-leading financial executive Viviane Monges to Board of Directors ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel
LAUSANNE, Switzerland, Jun 11, 2021--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that shareholders approved all of the resolutions as proposed by the Board of Directors at yesterday's Annual General Meeting (AGM).
ZYNLONTA™ LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCLSubgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65LAUS...
ZYNLONTA LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL Subgroup analyses include patients with double-
ADC Therapeutics SA: ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021, at 8:30 a.m. ET. A live webcast of the presentation will be available via the Events Presentations page in the Investors section of ADC Therapeutics' website, ir.adct...